HC Wainwright reaffirmed their buy rating on shares of Palatin Technologies (NYSEAMERICAN:PTN – Free Report) in a research report report published on Thursday, Benzinga reports. They currently have a $17.00 price objective on the biopharmaceutical company’s stock.
Palatin Technologies Trading Up 0.9 %
NYSEAMERICAN PTN opened at $1.10 on Thursday. The firm has a market cap of $21.51 million, a PE ratio of -0.53 and a beta of 0.99. Palatin Technologies has a 1-year low of $0.68 and a 1-year high of $5.65.
Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report) last posted its earnings results on Tuesday, October 1st. The biopharmaceutical company reported ($0.51) earnings per share for the quarter. As a group, analysts forecast that Palatin Technologies will post -2.03 EPS for the current fiscal year.
Institutional Inflows and Outflows
About Palatin Technologies
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.
Read More
- Five stocks we like better than Palatin Technologies
- Transportation Stocks Investing
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What is a Secondary Public Offering? What Investors Need to Know
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- Election Stocks: How Elections Affect the Stock Market
- The Downtrend in UPS Stock Isn’t Over Yet
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.